锶89在肺癌骨转移治疗中的应用分析  

Application of strontium 89 in treatment of bone metastasis from lung cancer

作　　者：王亚南[1] WANG Ya-nan(Department of Nuclear Medicine,Jiaozuo City People?s Hospital,Jiaozuo,Henan 454000,China)

机构地区：[1]焦作市人民医院核医学科

出　　处：《临床肺科杂志》2020年第1期92-95,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的分析锶89在肺癌骨转移治疗中的临床应用疗效,以指导其在肺癌骨转移患者中的临床应用。方法选取我院2013年1月~2017年12月期间收治的肺癌骨转移患者90例为研究对象,所有患者均经病理证实明确属于肺癌骨转移。随机将研究对象分为两组,1组选择锶89联合唑来膦酸治疗,2组选择放疗联合唑来膦酸治疗,随后即监测患者两组研究对象骨痛动态变化、血常规、肝肾功及骨扫描病灶变化。结果锶89联合唑来膦酸组骨痛反应情况及病灶消退情况明显优于放疗联合唑来膦酸组(P<0.05)。结论锶89联合唑来膦酸能有效提高治疗肺癌骨转移患者表现出的骨痛症状,相较于放疗能显著提高临床治疗效果,且较化疗具有骨髓抑制较轻的临床特点。Objective To analyze the clinical application of strontium 89 in treatment of bone metastasis of lung cancer to guide its clinical application in patients with bone metastases from lung cancer.Methods 90 patients with bone metastases from lung cancer admitted to our hospital from January 2013 to December 2017 were selected as subjects.All patients were confirmed by pathology to be bone metastasis from lung cancer.The subjects were randomly divided into two groups.The study group was treated with strontium 89 combined with zoledronic acid,and the control group was treated with radiotherapy combined with zoledronic acid,and then they were monitored for dynamic changes in bone pain,blood routine,liver and kidney.Results The bone pain response and lesion regression of the study group were significantly better than those of the control group(P<0.05).Conclusion Strontium 89 combined with zoledronic acid can effectively improve the symptoms of bone pain in patients with bone metastasis from lung cancer.Compared with radiotherapy,it can significantly improve the clinical treatment effect,and has clinical features of less bone marrow suppression than chemotherapy does.

关 键 词：锶89 肺癌 骨转移 

分 类 号：R73[医药卫生—肿瘤]